Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male

Adya, Keshavmurthy A; Inamadar, Arun C; Albadri, Warood

doi:10.1111/dth.15040

Cited by 21 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pityriasis rosea is a complication that appeared within 22 days and resolved within 12 weeks of vaccination [ 1 , 2 , 16 , 17 , 21 , 23 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. It was associated with BNT162b2 vaccination in most patients (71.9%; 41 of 57 eruptions, Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…2 There seem to be considerable differences between vaccine-induced PR and PR-like eruption in terms of clinical and histopathological findings. 3 The present case Abdullah et al 4 Cyrenne et al 5 Akdaş et al 6 Carballido et al 7 Temiz et al 8 Adya et al 9 Marcantonio administration; it tends to be itchy, widespread, and confluent compared to the classical PR. 3 Moreover, mucous membranes are more likely to be affected, the herald patch is not prominent and patients commonly do not have prodromal symptoms in PR-like eruption.…”

Section: Atypical Pityriasis Rosea Associated With Mrna Covid-19 Vaccinementioning

confidence: 65%

“…Similar to our case, Temiz et al8 reported five cases of atypical PR such as purpuric and vesicular forms developed after COVID-19 vaccination in a study of 31 patients. On the other hand, Adya et al9 observed another case of papulovesicular PR-like eruption in a young male patient 4 days after the first dose of recombinant COVID-19 vaccine. SARS-CoV-2 induced lymphopenia and functional impairment of CD4 + T cells might result in the reactivation of HHV-6 and HHV-7 thereby inducing PR and PR-like eruption after COVID-19 vaccine application 12.…”

mentioning

confidence: 99%

Atypical pityriasis rosea associated with mRNA COVID‐19 vaccine

Bostan

Jarbou

2021

Journal of Medical Virology

View full text Add to dashboard Cite

“…reported a patient whose cutaneous histopathologic examination revealed epidermal spongiosis, perivascular lymphocytic infiltrate in the papillary dermis, and extravasated red blood cells in the papillary and reticular dermis. 10 Another study by Akdas et al. demonstrated focal parakeratosis in mounds with exocytosis of lymphocytes, spongiosis in the epidermis, and extravasated red blood cells in the dermis.…”

Section: Discussionmentioning

confidence: 97%

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

Wang

Chen

Liu

2022

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. During this pandemic, acute COVID-19 infection has been related to PR or PR-like eruptions in several cases. Various COVID-19 vaccines associated with PR-like eruptions were rarely reported. Herein, we report a case of cutaneous PR-like eruptions following COVID-19 mRNA-1273 vaccination.

show abstract

Post Covid‐19 vaccination papulovesicular pityriasis rosea‐like eruption in a young male

Cited by 21 publications

References 8 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Atypical pityriasis rosea associated with mRNA COVID‐19 vaccine

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

Contact Info

Product

Resources

About